Home / Learn / Immunotherapy / View All IO Resources

View All IO Resources

Here is a comprehensive list of all of our immuno-oncology resources. Enter your search terms in the box below to filter your results.

Displaying results 21 - 40 of 44

  • Prev
  • 1 2 3 Next
    Lee Schwartzberg, MD, FACP, Chair, ACCC IO Institute Executive Committee, shares his perspective on immuno-oncology (IO) highlights from 2018 and what next steps in the IO journey may be in 2019.
    Determining the best personalized treatment for a patient will require input from a team of physicians, ideally with access to a patient’s information over time and across multiple modalities. Collecting data in a consistent, secure, and scalable manner with the ability to share across disciplines will be vital to furthering personalized medicine.
    The paradigm-changing advancements accompanying immunotherapy for cancer continue to require innovation in care delivery. Telehealth is a natural innovation partner for immuno-oncology when applied to patient-reported outcomes, provider education, and clinical trial enrollment.
    As with other high-cost treatments, integration of immunotherapies into practice requires a thorough understanding of payer policies and requirements for reimbursement. Sarah Hudson-DiSalle, PharmD, RPh, shares key steps for successful reimbursement for cancer immunotherapies.
    As a genitourinary medical oncologist specializing in immunotherapy for kidney and bladder cancers, I am continually striving for more ways to connect with and learn from my patients. The emerging availability of immuno-oncology (IO) drugs for the conditions I treat, as well as many other cancer types, has generated tremendous excitement amongst patients and oncologists, but there still is so much …
    November 1, 2018
    Presenters: Ali McBride, PharmD, MS, BCOP, Clinical Coordinator, Hematology/Oncology, The University of Arizona Cancer Center Igor Puzanov, MD, MSCI, FACP, Director, Early Phase Clinical Trials Program, Chief of Melanoma, Roswell Park Cancer Institute Review the latest IO approvals and new indications and hear about IO combination therapies, combination considerations, and how to approach IO doublet …
    Emergency physicians are partners in providing care to your acutely ill patients. Since emergency physicians’ experience with and exposure to the novel immunotherapies is relatively limited, it is important that ED physicians and nurses are aware of the indications for these agents and informed on potential acute and chronic complications of immunotherapy for cancer.
    A forthright conversation between the treating clinician, patient and family members on the importance of self-reporting adverse events must take place prior to consideration of combination immunotherapy.
    Immune-related adverse events (irAEs) are a complex category of symptoms driven by anti-cancer immunotherapy treatments. The use of IO has burgeoned since the approval of ipilimumab in 2011 through multiple approvals of anti-PD-1/PD-L1 drugs and most recently CAR-T therapies, and so too has the number of recognized irAEs.
    Survivorship care planning requires communication, care coordination, and education. Since immune-related adverse events are still being discovered, these discussions are even more imperative.
    Research nurse Joannne Riemer, RN, BSN, started her position at Johns Hopkins Medical Institution in 2010. Within six months, she was working with checkpoint inhibitors. From her vantage point in clinical trials research, she discusses the many changes in IO clinical trials patient selection over the last eight years.
    ACCC Immuno-Oncology Institute Executive Committee Chair Lee Schwartzberg, MD, FACP, highlights his top picks for compelling, potentially practice-changing immunotherapy abstracts presented during the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting. Dr. Schwartzberg is Chief, Division of Hematology Oncology; Professor of Medicine, University of Tennessee; and Executive Director, West …
    The Association of Community Cancer Centers recently spoke with Robyn Stacy-Humphries, MD, who was diagnosed with lymphoma in 2011, about her experience of treatment with CAR T-cell therapy in a clinical trial at the James Cancer Hospital at Ohio State University in Columbus, Ohio.
    To learn more about a unique approach to combining oncology and subspecialist expertise toward the goal of effective irAE management, the ACCC Institute for Clinical Immuno-Oncology spoke with medical oncologist Ryan Weight, DO, MS from the Sidney Kimmel Cancer Center (SKCC) of the Thomas Jefferson University, Philadelphia, Pennsylvania.
    Experts from the Saint Agnes Cancer Institute in Baltimore, Maryland hosted an Institute for Clinical Immuno-Oncology (ICLIO) Visiting Experts workshop to accelerate their learning about managing patients being treated with immuno-oncology (I-O) agents.
    November 29, 2017
    View the archived webinar: The Microbiome in Cancer Immunotherapy with expert presenter, Sandip Patel, MD, Assistant Director, Cancer Immunotherapy Programs, Center for Personalized Cancer Therapy, UC San Diego Moores Cancer Center. Learn how the microbiome could potentially be used to predict and enhance response to I-O therapy and to recognize patients who could be at risk for developing immune-related …

    Displaying results 21 - 40 of 44

  • Prev
  • 1 2 3 Next